What's Happening?
Orsini, a leader in rare disease pharmacy solutions, has been selected as the exclusive specialty pharmacy and home infusion partner for Denali Therapeutics' AVLAYAH (tividenofusp alfa-eknm). AVLAYAH is an FDA-approved
enzyme replacement therapy designed to treat neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients. This partnership will enable Orsini to provide comprehensive home infusion support, allowing patients to receive treatment in the comfort of their homes. The therapy is aimed at breaking down sugar molecules that accumulate in the body due to a lack of necessary enzymes, which can lead to progressive cellular damage affecting physical and cognitive development.
Why It's Important?
This partnership is crucial for advancing the treatment of Hunter syndrome, a rare genetic disorder. By facilitating home infusion services, Orsini enhances patient access to this critical therapy, potentially improving adherence and outcomes. The collaboration underscores the importance of integrated care models in managing rare diseases, where specialized treatments require coordinated efforts between pharmaceutical companies and healthcare providers. This development also highlights the growing trend of home-based healthcare solutions, which can offer convenience and reduce the burden on healthcare facilities. The partnership is a significant step in ensuring that patients with rare diseases receive timely and effective treatment.
